PeptideInjectableMyostatin inhibitorAnabolic peptide

GDF-8 (Myostatin) Inhibitor Peptide

Also known as Myostatin inhibitor peptide · GDF-8 blocker

Written by enwyReviewed 5 Aug 20261 sources0 comments

Peptides sold as GDF-8 (myostatin) inhibitors are marketed to block myostatin and increase muscle mass. While myostatin blockade is a validated biological target, the specific peptides sold in this space lack any human trial data, and approved biologic myostatin inhibitors have repeatedly failed to improve function in trials.

01 Overview

Myostatin (GDF-8) is a negative regulator of skeletal muscle growth; loss-of-function mutations produce dramatic muscle hypertrophy in animals and rare humans. This makes myostatin an attractive target, and pharma has developed antibodies and traps (bimagrumab, stamulumab, trevogrumab) — several of which increased lean mass but failed to improve strength or clinical endpoints.\n\nThe short 'GDF-8 inhibitor peptides' sold by research-chemical vendors are not those validated biologics. Their identity, purity and myostatin affinity are usually undocumented, and no controlled human data support them. Any anabolic claim rests on extrapolation from the broader myostatin literature.

02 Mechanism

Purported to bind or antagonise myostatin/activin receptor signalling (ActRIIB), relieving the brake on satellite cell proliferation and muscle protein accretion.

03 Dosing

Tier	Dose	Route	Notes
Anecdotal	1–5 mg/wk	SubQ	No validated protocol; vendor-suggested only.

04 Effects

Effect	Magnitude	Evidence
Increased lean muscle massMyostatin blockade increases muscle mass in animals; the specific vendor peptides are unproven in humans.	variable	Preclinical
Reduced fat massActRIIB pathway blockade reduced adiposity in animal models.	n/a	Preclinical

05 Side effects

Effect	Severity	Frequency	Evidence	Countermeasures
Muscle gain without strength gainApproved myostatin-pathway biologics increased lean mass but failed to improve strength or function in trials.	Mild	Seen with biologics	Clinical
Unknown purity and immunogenicityUnregulated peptides may be mislabeled or contaminated, risking injection-site or immune reactions.	Moderate	Unquantified	Unconfirmed

06 Legal status

United States

Research chemical; WADA-prohibited class

Myostatin inhibitors are banned in sport (WADA S4.3). · as of Jan 2026

07 References

Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivityPLoS One, 2011

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.